About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The goal of the Shock, Organic Dysfunction and Resuscitation Research Group (SODIR) is comprehensive, innovative research into the areas of shock, acute respiratory failure, acute kidney failure, organic dysfunction, resuscitation and critical patient monitoring. In addition, the research group has a special interest in applying artificial intelligence as an instrument to find innovative solutions for critical patients.
The research line in neurocritical pathology research line, led by Dr. A. Sanchez, studies HSA and specifically its evolutionary complications such as the development of late ischemic neurological deficit and myocardial dysfunction. Refractory epileptic status and delirium are also areas of interest. This line has an ongoing thesis (Dr. M. Santafé).
IP: Anna Sánchez Corral
The objective of the sepsis research line is the study of biomarkers that allow the early identification of the septic patient as well as the prognostic stratification of these patients. For SODIR, the study of microbiological diagnosis from molecular identification studies is also extremely important. The research lines in sepsis and infectous diseases are currently working collaboratively with Microbiology Department in several research projects. Among them, we should specifically highlight the RAIS study (Scalable, point-of-care and label free microarray platform for rapid detection of Sepsis, H2020-ICT-2014-1, Grant Agreement no. 644956) financed by European Commission that has the objective of developing a platform that will allow the early identification of several inflammatory mediators of sepsis and some of the most frequent microorganisms associated with severe sepsis and septic shock.
SODIR has created and developed the Sepsis Biobank in collaboration with de Microbiology Research Group of Vall d'Hebron University Hospital. The Sepsis Biobank of Vall d'Hebron University Hospital, co-directed by Juan Carlos Ruiz-Rodríguez, is a unit to support biomedical research that aims to make available to the scientific community samples of blood, plasma and serum of patients with sepsis and septic shock. The samples of Sepsis Biobank are obtained from septic patients with activation of the sepsis code of Vall d'Hebron University Hospital. The Sepsis Biobank, the first of Spain and the second of Europe, should be a tool to facilitate and promote biomedical research in sepsis in the scientific community. Currently two projects are already using samples of the BBS in their research.
IP: Juan Carlos Ruiz Rodriguez
IP: Xavier Nuvials Casals, Judith Sacanell Lacasa
The study will be conducted in the Intensive Care Medicine Service of the Vall d’Hebron University Hospital and will validate the prognostic value of the NLRP3 biomarker.
SOFA-2 is being updated after thirty years to incorporate advances in diagnosis, monitoring and life support.
On European Antibiotic Awareness Day, we highlight the importance of using these medications responsibly and finding innovative solutions to combat this issue.
